This statistic shows the top therapy areas worldwide by projected spending in 2028, in billion U.S. dollars. By 2028, spending on oncology is projected to be at some 440 billion U.S. dollars. Immunology is projected to be second with around 192 billion dollars of spending.

Keytruda is projected to stay the top-ranked drug worldwide based on sales in 2025, with some 31 billion U.S. dollars. This statistic displays the expected top drugs in 2025 based on sales projections as of December 2024. It has to be mentioned that Novo Nordisk's brands Ozempic and Wegovy are, in fact, the same drug (generic name semaglutide), where only dosage and dose form define if it is used for diabetes or weight loss. It is very similar in the case of Eli Lilly's Mounjaro and Zepbound which are basically one and the same drug (generic name tirzepatide). Oncology's dominance in pharmaceutical revenues Cancer treatments are becoming increasingly crucial in the pharmaceutical landscape. Keytruda's projected sales for 2025 underscore this trend, while the drug's revenue increased by more than four billion dollars between 2023 and 2024. This growth is part of a larger pattern in global oncology spending, which exceeded 250 billion U.S. dollars globally in 2024, almost doubling from five years earlier. The substantial investment in cancer treatments is likely to continue, with major pharmaceutical companies like Johnson & Johnson, AstraZeneca, and Merck expected to be the oncology market leaders by 2030. Market dynamics and company performance Merck & Co. has seen its overall revenue increase to 64 billion in 2024, driven largely by its oncology franchise. The company's commitment to innovation is evident in its record-high R&D spending in 2023. This focus on research and development is crucial for maintaining competitiveness in the industry, as demonstrated by the changing rankings of top-selling drugs. For instance, AbbVie's Humira, once a blockbuster, dropped out of the top 10 best-selling drugs in 2024 due to patent expiration, highlighting the constant need for pharmaceutical companies to innovate and develop new products to maintain their market position.

Global spending on medicine continues to grow. In 2022, approximately 1.48 trillion U.S. dollars had been spent on medicines, up from just 887 billion U.S. dollars in 2010. That number is expected to increase to over 1.9 trillion by the year 2027. Spending on medicines has increased everywhere globally. However, the United States takes the lead in total medicines spending globally and is expected to remain the top country for medicines spending through 2027.

Global pharmaceutical industry

Globally, the pharmaceutical industry is a growing industry fueled by aging populations and new drugs to treat rare and specialty diseases. Regionally, the pharmaceutical industry generates most of its revenues in the North American and European markets. Within all markets globally the top therapeutic class is oncology, followed by antidiabetics.

Top pharmaceutical companies

There are several large pharma companies that participate in the global pharmaceutical industry. As of 2021, U.S.-based pharmaceutical company Johnson & Johnson was the top pharmaceutical company based on market capitalization. Among pharmaceutical companies, some have produced more new drugs than others. The U.S. and Europe are responsible for the largest number of new pharmaceutical substances from 2017 to 2021.

Snapshot img

Over-The-Counter (OTC) Drug Market Size 2024-2028

The over-the-counter (OTC) drug market size is forecast to increase by USD 56.1 billion at a CAGR of 6% between 2023 and 2028.

The market growth is driven by several factors, including the introduction of new products, the increasing prevalence of diseases prompting higher usage of over-the-counter (OTC) drugs, and supportive regulatory environments. As pharmaceutical companies continue to innovate and launch new drugs, the market expands to accommodate these offerings. An e-pharmacy operates as an internet-based company selling medications, encompassing both legitimate and illegitimate outlets, predominantly in countries like India. 
Furthermore, the rising incidence of various diseases contributes to a higher demand for OTC drugs, further fueling market growth. Current trends indicate growth in e-commerce, including online shopping for prescription and non-prescription drugs, notably drug medications. Additionally, favorable regulations that support the availability and accessibility of OTC drugs also play a significant role in driving market expansion.

What will be the Size of the Over-The-Counter (OTC) Drug Market During the Forecast Period?

Request Free Sample

The market encompasses a significant portion of consumer healthcare spending, particularly in sectors such as pharmacies and hospitals. The B2C spend on OTC drugs is driven by the sales of self-medication associations for minor ailments like cough, cold, allergies, pain, fever, acidity, and diarrhea. Pharmacies and hospitals serve as crucial access points for consumers seeking these products. The OTC Drug Market modeling approach considers various factors, including patent expiry concerns for Pharma giants, substance abuse, incorrect diagnosis, and drug abuse. Kidney failure, memory loss, heart problems, and fatal cases are potential health risks associated with incorrect use or misdiagnosis of OTC drugs.
Pharmacists and doctors play essential roles in ensuring the safe and effective use of OTC drugs. They provide valuable advice and guidance to consumers, helping them make informed decisions about their health and medication choices. OTC drugs cater to a wide range of health concerns, making them an indispensable part of the healthcare system.

How is this Over-The-Counter (OTC) Drug Industry segmented and which is the largest segment?

The over-the-counter (OTC) drug industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Offline
  Online


Route Of Administration

  Oral
  Topical
  Parenteral
  Others


Geography

  North America

    US


  Europe

    Germany
    UK


  Asia

    China
    Japan


  Rest of World (ROW)

By Distribution Channel Insights

The offline segment is estimated to witness significant growth during the forecast period.

The market caters to various health conditions, including diarrhea and skin-related issues, through nonprescription medicines. Pharmaceutical companies manufacture and distribute these drugs, ensuring easy availability and affordability. Patient awareness programs play a crucial role in promoting self-medications. Retail pharmacy chains, such as Walgreens with over 9,000 locations in the US, serve as primary distribution channels. Guidelines and peer-reviewed journals provide essential clinical scenarios for prescribing OTC drugs. Global OTC markets continue to expand, driven by the growing need for accessible and cost-effective medicines.

Get a glance at the market report of share of various segments Request Free Sample

The offline segment was valued at USD 95.90 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 42% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The Over-the-Counter (OTC) Drugs market in North America is anticipated to expand due to various factors, including the increasing population and disposable income.

For more insights on the market size of various regions, Request Free Sample

Self-medication practices for conditions like diarrhea and skin-related issues are prevalent, with the easy availability and affordability of OTC medicines being significant drivers. Pharmaceutical companies are investing in patient awareness programs to expand the nonprescription drugs market. The rising prevalence of chronic conditions and the cost-effectiveness of OTC drugs are also contributing to market growth. Peer-reviewed journals and clinical scenarios provide guidelines for the appropriate use of

According to Cognitive Market Research, the global Pharmaceutical CXO market size will be USD XX million in 2024. It will expand at a compound annual growth rate (CAGR) of 15.00% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 13.2% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD XX million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 17.0% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.4% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 14.7% from 2024 to 2031.
The CRO category is the fastest growing segment of the Pharmaceutical CXO industry

Market Dynamics of Pharmaceutical CXO Market

Key Drivers for Pharmaceutical CXO Market

Growing Demand for Biologics and Specialty Drugs to Boost Market Growth

The increasing development and production of biologics, including biosimilars, has significantly boosted the demand for specialized Contract Manufacturing Organization (CMO) services. Recent data reveals that therapeutic areas with biosimilars introduced in the past three years see an average market share of 75%. In contrast, therapeutic areas with biosimilars launched before 2019 have experienced a lower average market share of 39% over three years. In the U.S., the presence of biosimilars has led to substantial savings in drug expenditures, with an estimated $21 billion saved over the past six years due to biosimilar competition. For just the second quarter of 2022, the savings in drug spending reached approximately $3.2 billion. Both the EU and U.S. markets account for 90% of cumulative biosimilar usage, measured by sales. These trends underscore the growing demand for advanced manufacturing technologies and expertise required to produce complex biologic drugs. As a result, the global Pharmaceutical CxO market is expected to see increased growth. The rise in biosimilars drives the need for CMOs with specialized capabilities to handle the complexities of biologic production, thus creating significant opportunities for growth and expansion in the CxO sector.

Increasing Drug Development Costs and Complexity to Drive Market Growth

The cost of developing new drugs has significantly increased due to the growing complexity of drug development and rigorous regulatory demands. In 2019, the pharmaceutical industry invested $83 billion in research and development (R&D). When adjusted for inflation, this figure is approximately ten times higher than the annual R&D spending of the 1980s. During the twelve months from July 2021 to July 2022, 1,216 products saw price increases that surpassed the inflation rate of 8.5% for that period. On average, the price of these drugs rose by 31.6%. In some cases, drug prices surged by over $20,000, representing a dramatic increase of up to 500%. To manage these escalating costs, pharmaceutical companies are increasingly relying on Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs). These organizations provide specialized expertise and advanced technologies that streamline the drug development process, helping to reduce both costs and time-to-market.

Restraint Factor for the Pharmaceutical CXO Market

Regulatory and Compliance Challenges Will Limit Market Growth

The pharmaceutical industry is highly regulated, and compliance with global and regional regulations can be complex and costly. CROs and CMOs must navigate various regulatory requirements across different markets, which can lead to delays and increased operational costs. Regulatory standards are constantly evolving, and staying compliant with these changes requires continuous updates to processes and systems, adding to operational complexity and costs. Ensuring consistent quality across different CROs and CMOs can be challenging. Variability in quality standards and practices among service provi...

Medication Market Outlook

The global medication market size was valued at approximately USD 1.2 trillion in 2023 and is expected to reach USD 1.8 trillion by 2032, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period. This growth is primarily driven by increasing prevalence of chronic diseases, advancements in pharmaceutical research, and rising healthcare expenditure across the globe. The market is witnessing a robust expansion due to the ever-growing demand for effective and innovative medication solutions addressing various health issues. Furthermore, the rising awareness among consumers regarding healthcare and wellness is propelling the market towards a steady growth trajectory.

One of the foremost growth factors influencing the medication market is the surge in chronic diseases worldwide, such as cardiovascular diseases, diabetes, and cancer, which necessitates continuous medication and treatment. As the global population continues to age, disorders associated with aging are also becoming more prevalent, increasing the demand for medications specifically targeting these conditions. In addition, lifestyle changes and unhealthy habits have contributed significantly to the prevalence of these diseases, particularly in urban areas where sedentary lifestyles and high-stress environments are common. This escalating incidence of chronic conditions demands a higher consumption of medications, thus driving the market growth.

Technological advancements in the pharmaceutical industry are another critical factor contributing to the market's growth. Cutting-edge research and development activities have led to the introduction of novel drugs and therapies, enhancing the efficacy and safety of medications. Precision medicine, for instance, is making significant strides, providing personalized treatment plans that are highly tailored to individual patient needs. Moreover, the advent of biologics and biosimilars, which offer significant therapeutic benefits, is further boosting the medication market. Pharmaceutical companies are heavily investing in R&D to innovate and develop advanced medications, which is expected to continue fueling market expansion.

The increasing healthcare spending by governments and individuals is also a substantial growth driver for the medication market. Many countries are expanding their healthcare budgets and implementing favorable policies to ensure better access to medicines, thereby stimulating market growth. Infrastructural developments, such as the expansion of healthcare facilities and improvements in healthcare delivery systems, particularly in emerging economies, are also contributing significantly to the market's expansion. Additionally, growing consumer awareness and demand for high-quality healthcare services are bolstering the demand for various medications, ensuring a positive market outlook in the coming years.

From a regional perspective, North America currently dominates the medication market due to its robust healthcare infrastructure, significant R&D investments, and high adoption rate of new pharmaceuticals. The presence of major pharmaceutical companies and favorable regulatory frameworks also contribute to this region's leading position. Meanwhile, the Asia Pacific region is anticipated to experience the highest growth rate during the forecast period. This is attributed to the increasing population, rising healthcare expenditure, and improving access to healthcare facilities in countries such as China and India. Additionally, the growing prevalence of chronic diseases in this region is further fueling the need for medications, thereby expanding the market.

Product Type Analysis

Within the medication market, product type segmentation plays a crucial role in understanding consumer preferences and market dynamics. Prescription medications hold a significant share of the market due to their essential role in treating chronic diseases and serious health conditions that demand professional medical oversight. These medications are often intricately designed and tailored to provide specific therapeutic effects, which makes them indispensable in healthcare. With an aging global population and the increasing incidence of chronic illnesses, the demand for prescription medications is bound to rise, ensuring a solid market presence in the coming years.

Over-the-Counter (OTC) medications offer a convenient and accessible alternative for consumers seeking immediate relief from common ailments such as cold, flu, headaches, and minor aches. The OTC segment continues to thrive due to its ease

Retail Drug Market Overview The global retail drug market is projected to grow from USD XXX million in 2025 to USD XXX million by 2033, exhibiting a CAGR of XX% from 2025 to 2033. The growing prevalence of chronic diseases, rising healthcare costs, and increased accessibility to healthcare services are key drivers of market growth. Key trends in the market include the adoption of digital technologies, expansion of pharmacy benefit management services, and the rise of specialty pharmacies. Key Players and Regional Analysis Major players in the retail drug market include CVS Caremark, Rite Aid, Target, Walgreens, and Walmart. The North American region dominates the global market, followed by Europe and Asia Pacific. Emerging markets in these regions are expected to drive market growth over the forecast period. Key segments in the market include application (prescription drugs, over-the-counter drugs) and type (brand-name drugs, generic drugs). The market is fragmented, with numerous local and regional players operating in different geographies.

According to Cognitive Market Research, the global Biologics Drug Development market size will be USD 7551.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 8.50% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 3020.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.7% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2265.36 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 1736.78 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.5% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 377.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 151.02 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.
The In-House category is the fastest growing segment of the Biologics Drug Development industry

Market Dynamics of Biologics Drug Development Market

Key Drivers for Biologics Drug Development Market

Increasing the investment in healthcare infrastructure to Boost Market Growth

The increasing expenditure on healthcare is another significant factor that influences the growth rate of the biologics market, as it contributes to the enhancement of its infrastructure. Additionally, many government organizations are striving to enhance the healthcare infrastructure by increasing funding, which will have a further impact on the market dynamics. In addition, the biologics market will be expanded by the increasing number of initiatives by public and private organizations to raise awareness. In addition, the biologics market will expand due to the increasing geriatric population and the sedentary lifestyle of the general populace. Additionally, the market's growth rate will be bolstered by favorable reimbursement policies. For instance, according to the World Health Organization (WHO), chronic diseases result in the deaths of over 41 million individuals annually on a global scale. The most prevalent chronic disease, cardiovascular disease, results in the deaths of 17.9 million individuals annually. Cancer, diabetes, and respiratory disorders are the subsequent disorders. A total of 80% of chronic disease mortality is attributable to these four categories.

Growth in the quantity of research and development initiatives to Drive Market Growth

The market's expansion is stimulated by an increase in the quantity of research and development activities. This will generate advantageous prospects for the expansion of the biologics market. Furthermore, scientists and researchers are conducting research on species and expression systems to develop the productivity of biological products. Furthermore, many pharmaceutical companies are engaged in research and development (R and D) to enhance the efficacy of oral medications for Crohn's disease and rheumatoid arthritis. In addition, the market's growth rate will be further accelerated by the increasing number of drug approvals and launches. Moreover, the biologics market will experience favorable growth opportunities during the forecast period as a result of the expansion of emerging markets and the growing investment in the development of cutting-edge technologies.

Restraint Factor for the Biologics Drug Development Market

Expensive development expenses, will Limit Market Growth

The development of biologics is a complex and time-consuming process, which presents obstacles for those who are responsible for the development of biologics. These challenges are caused by the significant financial investment that is necessary for the development of biologics. It is possible that it will take years from the original investment to the approval of the market. In order to meet the requirements of this prolonged timetable, continual clinical trials, research-based activities, and manufacturing procedures are required. This results in a rise in the total expenditures. There is a possibility that this issue may prevent manufacturers from joining the market, which would in turn hinder the expansion of ...

Pharmaceutical Packaging Market size was valued at USD 135.46 Billion in 2023 and is projected to reach USD 237.18 Billion by 2031, growing at a CAGR of 8.00 % from 2024 to 2031.

Key Market Drivers
Increase in Pharmaceutical Expenditures: The rise in worldwide healthcare expenditure is a major driver of the pharmaceutical packaging business. The World Health Organization (WHO) estimates that worldwide health spending will reach $8.3 trillion in 2020, accounting for 10% of global GDP. This growth in spending corresponds to increased demand for medications, creating a greater need for efficient packaging solutions that ensure product safety and efficacy.
Growth in Biopharmaceuticals: The biopharmaceutical industry is rapidly growing, demanding innovative packaging solutions. The European Federation of Pharmaceutical Industries and Associations (EFPIA) reported that the biopharmaceutical sector accounted for 38% of the entire pharmaceutical market in 2020, with biologics advances expected to drive growth. Biopharmaceuticals frequently require specialized packaging to preserve stability and integrity, which fuels demand in the Pharmaceutical Packaging Market.
Regulatory Requirements and Safety Concerns: Stringent laws governing medicine safety and packaging are pushing innovation in pharmaceutical packaging. The United States Food and Drug Administration (FDA) has announced rules requiring tamper-evident packaging for over-the-counter medications, indicating a rising emphasis on consumer safety. According to the FDA, inappropriate packaging has been related to adverse occurrences, making regulatory compliance a vital consideration for pharmaceutical companies, driving up demand for innovative packaging solutions.

In 2023, research and development spending in the pharmaceutical industry exceeded 300 billion U.S. dollars globally. For comparison, R&D expenditures totaled 137 billion dollars in 2012. Pharmaceutical R&D includes all steps from the initial research of disease processes, the compound testing over pre-clinical, and all clinical trial stages. At a certain point in the process – mostly during the pre-clinical phase – a governmental authority is involved to overview, regulate, and ultimately approve the drug. In the United States, the Food and Drug Administration is the principal agency associated with processes. The pressure to innovate In comparison to other industries, pharmaceutical companies are more driven by the imperative to manufacture innovative products, and thus to spend significant amounts on research and development. This is largely due to the time-limited patent protection of drugs and the following threat of sales erosion through generic and biosimilar competition. Two major effects of patent expirations for the pharma industry are a specific high R&D intensity and a growing focus on specialty drugs to diversify their product portfolio. The latest trends For the last several years, major developments in pharmaceutical research and development have begun to change the R&D landscape. A growing number of drug manufacturers are outsourcing large parts of R&D, mostly to clinical research organizations (also contract research organizations), with the main aim to reduce costs. Another important development is the use of big data in clinical research. Thus, a predictive modeling is possible which uses clinical and molecular data to develop safer and more efficient drugs. Particularly, real-time or real-world evidence (RWE) is becoming a greater interest. This makes cooperation with technology companies necessary and includes data gathered from various sources, even that of social media.

Pharmaceutical Chemicals Market size was valued at USD 131.53 Billion in 2024 and is projected to reach USD 224.32 Billion by 2031, growing at a CAGR of 6.9% from 2024 to 2031.

Global Pharmaceutical Chemicals Market Drivers

Increasing Global Healthcare Expenditure: Rising healthcare spending worldwide drives the demand for pharmaceutical chemicals used in the production of essential medicines and healthcare products.
Growing Aging Population: The aging population demographic leads to higher incidence of chronic diseases and age-related health conditions, necessitating the development and production of pharmaceuticals, thus driving the demand for pharmaceutical chemicals.
Expanding Pharmaceutical Industry: The continuous expansion of the pharmaceutical industry, particularly in emerging markets, fuels the demand for active pharmaceutical ingredients (APIs), excipients, and other pharmaceutical chemicals.
Advancements in Drug Development: Innovations in drug discovery and development require a wide range of specialty chemicals and intermediates, driving demand for pharmaceutical chemicals that meet specific quality and regulatory standards.
Increasing Prevalence of Chronic Diseases: The rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer drives the need for effective pharmaceutical treatments, boosting demand for related chemicals and APIs.
Focus on Generic Drugs: The growing market for generic drugs, especially in developing countries, increases the demand for cost-effective pharmaceutical chemicals used in generic drug formulations.
Regulatory Support and Quality Standards: Stringent regulatory requirements and quality standards in pharmaceutical manufacturing necessitate the use of high-quality, compliant pharmaceutical chemicals, driving market growth.

According to Cognitive Market Research, the global active pharmaceutical ingredient market size will be USD 165245.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 7.2% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 66098.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.4% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 49573.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 38006.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 8262.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 3304.90 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.
The synthetic APIs category is the fastest growing segment of the active pharmaceutical ingredient industry

Market Dynamics of Active Pharmaceutical Ingredient Market

Key Drivers for Active Pharmaceutical Ingredient Market

Production Capacity Expansion in Pharmaceutical and Biopharmaceutical Companies to Boost Market Growth

Pharmaceutical and biopharmaceutical companies are expanding production capacities to meet the growing demand for active pharmaceutical ingredients (APIs). This expansion is driven by the increasing prevalence of chronic diseases, aging populations, and rising demand for innovative therapies. Companies are investing in new facilities, advanced manufacturing technologies, and scaling up existing operations to enhance API production. This growth supports drug development and ensures a stable supply chain, especially for high-demand medications. Additionally, regulatory support and partnerships are boosting the production of APIs, further driving the pharmaceutical market's expansion. For instance, in November 2023, Novo Nordisk announced plans to expand its existing manufacturing capacity by building a new API facility in Kalundborg, Denmark. An investment of more than USD 6 billion was made in the project to enhance capacity throughout the entire global value chain, from API production to packaging.

Favorable Regulations for R&D Facilities to Drive Market Growth

Favorable regulations for R&D facilities are boosting growth in the active pharmaceutical ingredient (API) market. Governments worldwide are implementing policies that support innovation in pharmaceutical research, including tax incentives, streamlined approval processes, and funding for R&D activities. These regulations encourage pharmaceutical companies to invest in developing new and improved APIs, which are essential for drug formulation. The supportive environment accelerates innovation, reduces costs, and enhances the competitiveness of API manufacturers, driving market expansion. It also fosters collaboration between academia, industry, and regulatory bodies, further advancing pharmaceutical development.

Restraint Factor for the Active Pharmaceutical Ingredient Market

Limited Availability of Raw Material Will Limit Market Growth

The limited availability of raw materials is a key challenge in the active pharmaceutical ingredient (API) market. API production relies heavily on specific raw materials, which are subject to supply chain disruptions, geopolitical issues, and environmental regulations. These constraints can lead to delays in drug manufacturing and higher production costs. Additionally, reliance on a few global suppliers, especially from countries like China and India, exacerbates the risk of shortages. As a result, pharmaceutical companies are increasingly seeking alternative sources and more sustainable raw material supply chains to mitigate these risks.

Impact of Covid-19 on the Active Pharmaceutical Ingredient Market

The COVID-19 pandemic significantly impacted the active pharmaceutical ingredient (API) market, disrupting global supply chains and highlighting dependency on specific regions, particularly China and India, for API production. Demand for APIs surged due to the increased need for medicat...

The global drug layering pellets market is anticipated to reach a valuation of approximately USD 4.3 billion by 2033, expanding at a CAGR of nearly 5.3% between 2025 and 2033. The increasing demand for oral drug delivery systems and the growing prevalence of chronic diseases are the key factors driving the market growth. Drug layering pellets are widely utilized in the pharmaceutical industry for the formulation of modified-release, targeted-release, and taste-masked drugs. These pellets offer advantages such as improved bioavailability, reduced side effects, and enhanced patient compliance. The market for drug layering pellets is segmented based on application, type, and region. In terms of application, the tablet segment holds a significant market share due to the extensive use of tablets in the pharmaceutical industry. The particle size below 500μm segment dominates the type segment, owing to the high demand for pellets with smaller particle sizes for better drug release and absorption. Geographically, North America accounts for the largest market share, driven by the presence of leading pharmaceutical companies and advancements in drug delivery technologies. Asia Pacific is expected to witness significant growth during the forecast period due to the rising healthcare expenditure and the increasing prevalence of chronic diseases in the region. This comprehensive report provides an in-depth analysis of the global drug layering pellets market, with a focus on its size, key trends, driving forces, challenges, and market share analysis. The report includes insights from industry experts and detailed forecasts for the future of the market.

Snapshot img

Pharmaceutical Contract Packaging Market Size 2024-2028

The pharmaceutical contract packaging market size is forecast to increase by USD 9.32 billion at a CAGR of 16.54% between 2023 and 2028.

The global pharmaceutical contract packaging market is experiencing steady growth, driven by rising R&D investments in the pharmaceutical industry and advancements in specialized packaging technologies. Key factors include the increasing trend of outsourcing packaging to reduce costs and improve efficiency, alongside growing demand for innovative solutions like child-resistant and anti-counterfeit packaging, spurred by regulatory requirements and market expansion.
This report provides a detailed resource for businesses, offering insights into market size, growth forecasts through 2028, and key segments like plastic bottles, which lead due to their cost-effectiveness and safety features. It explores trends such as the shift toward green packaging and addresses challenges like the high cost of advanced anti-counterfeit technologies, which can strain budgets but are critical for product integrity. The analysis is tailored for strategic planning, supply chain optimization, and market positioning.
For companies aiming to stay competitive in the global pharmaceutical contract packaging market, this report delivers practical data and perspectives on leveraging outsourcing trends and overcoming technological cost barriers, ensuring they can adapt to a dynamic and regulated landscape.

What will be the Size of the Pharmaceutical Contract Packaging Market During the Forecast Period?

Request Free Sample

The market's sizeable investment in production capacity expansion reflects the growing demand for packaging services for bioproducts, oncology drugs, high-potency drugs, antibody conjugates, steroids, and generic pharmaceuticals. Additionally, the growing demand for specialty pharmaceuticals, oncology drugs, vaccines, and biotech products is fueling the market, particularly in the areas of autoinjectors and pouches. The pharmaceutical packaging industry is also being influenced by the FMCG sector and health insurance trends, as insurers look for cost-effective solutions to manage drug delivery and distribution. Overall, the market for pharmaceutical contract packaging is expected to continue its growth trajectory, driven by these trends and challenges. Contract businesses offering ancillary services, such as bottle filling (plastic and glass), are also experiencing significant growth.

How is this Pharmaceutical Contract Packaging Industry segmented?

The pharmaceutical contract packaging industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Packaging

  Plastic bottles
  Blister packs
  Pouches
  Parenteral containers
  Pre-filled syringes


Type

  Primary
  Secondary
  Tertiary


Material

  Plastics & Polymers
  Paper & Paperboard
  Glass
  Aluminum Foil
  Others


Geography

  North America

    US
    Canada


  APAC

    China
    India
    Japan


  Europe

    France
    Germany
    Italy
    UK


  Middle East and Africa



  South America

By Packaging Insights

The plastic bottles segment is estimated to witness significant growth during the forecast period. Pharmaceutical contract packaging involves the provision of services for manufacturing, filling, and packaging pharmaceutical products by third-party companies. Plastic bottles, made from low-density polyethylene (LDPE), high-density polyethylene, or polypropylene materials, are commonly used as primary packaging for solid, liquid, and semi-liquid pharmaceuticals. Some contract packaging companies manufacture these bottles in-house, while others procure them from suppliers and offer only packaging services. The demand for plastic bottles is on the rise In the pharmaceutical industry due to their benefits, such as eliminating the need for tertiary packaging and ensuring product safety throughout the supply chain.

Pharmaceutical packaging materials, including silicone-based and sustainable options, are essential for the industry's growth, particularly for bioproducts, generic pharmaceuticals, and injectables. Cloud packaging companies offer flexible, profitable solutions for pharmaceutical corporations, enabling capacity expansions and innovation in drug delivery systems. The global pharmaceutical industry's growth, driven by economic growth, an aging population, and healthcare systems, increases the demand for contract packaging services. Contract packaging companies provide ancillary services, including autoinjectors, prefilled syringes, and specialized manufacturing, to meet the industry's evolving needs.

The industry's supply chain requires specialized equipment, log keeping, and da

The size of the Japan Pharmaceutical Industry market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 0.88% during the forecast period.Japan Pharmaceutical Industry, among other things, is one of the most mature in the world and always has products of good quality and stringent norms, especially about latest research and developments. The industry significantly benefits health on a global level through creation and manufacture of latest medications and medical equipment.They have a high level of capability in various therapeutic areas including oncology, gastroenterology, neurology, and cardiovascular disease. Japanese firms have a good history of developing innovative treatments and therapies, often leading the industry benchmarking. The regulatory regime in Japan is also more robust, hence ensuring drugs are safe and effective to be used.It is innovating and adapting to the challenges posed by aging demographics and rising healthcare costs.Japanese pharmaceutical companies are growing rapidly around the world, forming strategic alliances and conducting research and development, so they do not fall behind. Recent developments include: In April 2022, Takeda pharmaceuticals received manufacturing and marketing approval from the Japan Ministry of Health, Labour and Welfare (MHLW) for Nuvaxovid Intramuscular Injection (Nuvaxovid), a novel recombinant protein-based COVID-19 vaccine for primary and booster immunization in individuals aged 18 and older., In March 2022, Chugai Pharmaceutical Co. Ltd obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan for Vabysmo for Intravitreal Injection 120 mg/ mL (generic name: farcical), an anti-VEGF/anti-Ang-2 bispecific antibody for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema (DME).. Key drivers for this market are: Rising Geriatric Population and Increasing Burden of Chronic Diseases, Increasing Research and Development Activities Along with Growing R&D Investments. Potential restraints include: Stringent Regulatory Scenario. Notable trends are: Prescription Drugs Segment is Expected to Hold a Significant Share in the Market Over Forecast Period.

Snapshot img

Drug Discovery Technology Market Size 2024-2028

The drug discovery technology market size is forecast to increase by USD 27.31 billion at a CAGR of 9.2% between 2023 and 2028.

The market experiences significant growth due to the increasing prevalence of chronic conditions such as cardiovascular diseases and diabetes. This market is driven by the introduction of innovative small molecule drug candidates and advanced technologies to expedite the drug discovery process. However, intellectual property (IP) issues arising from patent expiration pose a challenge in the development and commercialization of new therapies. As healthcare expenditure continues to rise, the demand for effective treatments and cures remains high, creating opportunities for market participants. This report provides a comprehensive analysis of the market trends, growth drivers, and challenges in the drug discovery sector.

What will the size of the market be during the forecast period?

Request Free Sample

The market encompasses the processes involved in identifying and developing new chemical compounds with therapeutic potential. This market plays a pivotal role in addressing the unmet medical needs of chronic diseases such as cardiovascular diseases, diabetes, cancer, respiratory diseases, neurological disorders, and others. The scientific research community continues to explore innovative treatments using various techniques, including the application of artificial intelligence (AI) and genomics in drug discovery. Small molecule drug discovery remains a significant focus, as these compounds offer potential solutions for various therapeutic areas. Furthermore, preclinical testing and clinical trials are crucial stages in the drug discovery process. These stages ensure the safety and efficacy of lead compounds before they can be approved for widespread use. Pharmaceutical companies invest substantial resources in these stages to bring new drugs to market. Healthcare expenditure and patent expiration are key drivers for the drug discovery technology market. As chronic diseases continue to rise, there is a growing demand for new treatments. Additionally, with the expiration of patents on many blockbuster drugs, pharmaceutical companies are under pressure to discover and develop new therapeutics.
Cardiovascular diseases, diabetes, and cancer are among the leading causes of death and disability worldwide. In addition, antiviral drugs have also gained significant attention due to the ongoing COVID-19 pandemic. The development of effective treatments for these conditions remains a priority for the drug discovery technology market. Biopharmaceuticals, which include proteins, peptides, and monoclonal antibodies, are also a significant focus in the drug discovery technology market. Lifestyle changes and environmental factors, such as pollution, can contribute to the development of various diseases. Therefore, continued research in drug discovery is essential to address these health concerns. Innovations in drug discovery technology, such as AI and genomics, offer promising opportunities for the market. These technologies can help accelerate the discovery process, reduce costs, and improve the success rate of bringing new drugs to market.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Product

  Genomics
  Proteomics
  Bioinformatics
  High-throughput screening (HTS)
  Others


End-user

  Pharmaceutical and biotechnology companies
  Academic and research institutes
  CROs


Geography

  North America

    US


  Europe

    Germany


  Asia

    China
    India
    Japan


  Rest of World (ROW)

By Product Insights

The genomics segment is estimated to witness significant growth during the forecast period.

The market is experiencing notable progress, with the genomics segment leading the way. This sector is marked by the adoption of advanced technologies that improve the accuracy and speed of genetic analysis, which is essential for creating novel therapeutic interventions. Genomics, which entails examining an organism's entire deoxyribonucleic acid (DNA), including all its genes, plays a pivotal role in drug discovery. The capacity to sequence and analyze genomes has revolutionized the identification of genetic markers linked to diseases, paving the way for personalized treatments.

Additionally, recent breakthroughs in genomics are propelling the market forward, as companies introduce sophisticated solutions aimed at revolutionizing cancer therapy and managing neurological disorders, such as Alzheimer's and Parkinson's diseases. These advancements are driven by the increasing prevalence of conditions

According to Cognitive Market Research, the global Medicine market will be USD XX million in 2024 and will expand at a compound annual growth rate (CAGR) of 5.10% from 2024 to 2031.

North America held the major market share, more than 40% of the global revenue, with a market size of USD XX million in 2024. It will grow at a compound annual growth rate (CAGR) of 3.3% from 2024 to 2031.
Europe accounted for over 30% of the global USD XX million market size.
Asia Pacific held a market share of around 23% of global revenue, with a market size of USD XX million in 2024, and will grow at a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.
Latin America's Market will have more than 5% of the global revenue with a market size of USD 1XX million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.5% from 2024 to 2031.
The Middle East and Africa held the major market share, around 2% of the global revenue, with a market size of USD XX million in 2024. The market will grow at a compound annual growth rate (CAGR) of 4.8% from 2024 to 2031.
The hospital held the highest Medicine market revenue share in 2024.

Market Dynamics of Medicine Market

Key Drivers of Medicine Market

Growing Patient Awareness and Demand to Provide Viable Market Output

The growing patient awareness and demand significantly increase global demand. As patients become more informed about healthcare options, treatments, and preventive measures, they actively seek out solutions to address their health concerns. This increased awareness leads to a higher demand for pharmaceuticals, medical devices, and healthcare services. Patients are more inclined to participate in their own healthcare decisions, driving demand for innovative treatments and therapies. Additionally, advancements in technology and access to information empower patients to explore alternative medicine options, contributing to the expansion of the medicine market. Overall, the trend towards greater patient awareness and demand fuels growth and innovation within the healthcare industry.

For instance, in March 2021, in India, Hyderabad-based health supplements startup Fitday announced plans to launch 50 brick-and-mortar stores by 2023 across India with an investment of USD 8 million. This omnichannel startup has a product portfolio that includes vitamins, minerals, immunity boosters, sports nutrition products, and Ayurvedic herbs.

(Source: https://www.businesstoday.in/latest/corporate/story/health-supplements-startup-fitday-stores-india-hyderabad-website-covid-19-pandemic-isopure-nestle-and-optimum-nutrition-293276-2021-04-12)

New Launches to Propel Market Growth

The new launches aim to provide growth in the Market. Pharmaceutical companies invest heavily in research to introduce novel drugs that address unmet medical needs or offer improved efficacy, safety, or convenience compared to existing treatments. These new launches often target prevalent diseases such as cancer, cardiovascular conditions, or infectious diseases, driving market growth by expanding treatment options and improving patient outcomes. Additionally, regulatory approvals, advancements in biotechnology, and increasing healthcare expenditure globally further stimulate the introduction of new medicines. Consequently, the medicine market thrives on a cycle of innovation, with ongoing launches contributing to its dynamism and growth.

For instance, in November 2020 - Kunnath Pharmaceuticals, a manufacturer of herbal products, launched antiviral immunity booster capsules across India under the brand name 'Viromune.' Through this launch, the firm was looking to achieve a turnover of USD 266 million over the next three years.

(Source: https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/kunnath-pharmaceuticals-launches-antiviral-herbal-product-across-india/articleshow/79060893.cms?from=mdr)

Restraint Factors of Medicine Market

High Development Costs to Restrict Market Growth

The Medicine market faces challenges due to the high development costs. Pharmaceutical research and development demand extensive financial investments, encompassing preclinical studies, clinical trials, and regulatory compliance. These costs often soar due to stringent safety and efficacy standards, prolonged testing phases, and complex manufacturing processes. Additionally, the need for constant adaptation to evolving...

According to cognitive market research, the global orphan drugs market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

Orphan pharmaceuticals are pharmaceuticals that are used to diagnose and treat rare medical illnesses. These medications are developed to address a specific public health need and typically have a limited market because they are designed for a small patient population.
The rising R&D expenditures by major companies for the creation of innovative items are one of the crucial factors that dominate the worldwide market.
The biological orphan drug category is the result of key market participants supplying a greater number of biological products.
The fact that orphan pharmaceuticals in the US enjoy tax benefits, a user fee waiver, and seven years of marketing exclusivity following FDA clearance for a particular purpose is one factor contributing to the market's expansion.
Drug dosages supplied intravenously (IV) to patients with orphan illnesses must only be handled and monitored by qualified healthcare providers.

Market Dynamics of the Orphan Drugs Market

Key Drivers of the Orphan Drugs Market

The growing patient population with rare diseases is propelling the market growth.

About 300 million people are predicted to be impacted globally by recurrent, chronic, and uncommon diseases as well as a rise in the need for large-scale orphan medication manufacture. The need for pharmaceuticals that support the growth of the market is rising for rare illness medications, including Waardenburg Syndrome, von Willebrand illness, Yellow Fever, Diabetes Macular Edoema, Abetalipoproteinemia, Autism Spectrum Disorder, Von Hippel Lindau Syndrome, Yellow Nail Syndrome, and others. Furthermore, about 400 million individuals worldwide suffer from orphan diseases, even though they are uncommon. Approximately 7000 distinct forms of orphan diseases have been identified. Players in the orphan medication industry now have a tonne of opportunities. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-022-01026-w • For instance, according to an article published by Euronews in 2023, there are 5000 to 8000 rare diseases in Europe that affect the daily lives of almost 30.0 million people in the region and 300.0 million across the world. (Source:https://www.euronews.com/health/2023/06/15/30-million-europeans-affected-by-rare-diseases)

Government incentives and favorable regulations by the regulatory bodies for orphan drugs boost the market growth rate

To incentivize pharmaceutical companies to invest in research and development for rare diseases, the U.S. Congress passed The Orphan Drug Act in 1983. This act grants tax credits, grants, and exclusive marketing rights to pharmaceutical companies that manufacture orphan drugs. The governments provide advantageous laws for the development and approval of orphan medications, hence providing further assistance to the pharmaceutical industry. Additionally, through insurance coverage and payment regulations, governments have supported patient access to orphan medications and funded their research and development. • For instance, in October 2023, the Indian government launched the National Policy On Research and Development and Innovation in The Pharma-Med Tech Sector in India and the Scheme for The Promotion of Research and Innovations in The Pharma-Medtech Sector (PRIP). They focus on fostering research, development, and innovation in the pharmaceutical and medical technology sectors in India. The policy’s parts focus on rare diseases, gene therapy, orphan drugs, and precision medicines. (Source:https://pib.gov.in/PressReleasePage.aspx?PRID=1960812)

Restraints of the Orphan Drugs Market

High costs associated with drug development may hamper market growth

The market for orphan pharmaceuticals is predicted to expand slowly due to the high costs connected with these medication innovations; nevertheless, during the projection period, the industry's growth may be hampered by high per-patient treatment costs and regulatory limitations on profitability. Orphan medications are selectively available because of the rarity of orphan illnesses. Orphan medications are expensive due to their limited availability and significant investments in research & development. Furthermor...

Rx To Otc Switches Market size was valued at 34.93 USD Billion in 2024 and is projected to reach 51.22 USD Billion by 2030, growing at a CAGR of 4.90% during the forecast period 2024-2031.

Global Rx To Otc Switches Market Drivers

The market drivers for the Rx To Otc Switches Market can be influenced by various factors. These may include:

Savings for Patients and Healthcare Systems: Over-the-Counter (OTC) drugs often have lower costs than prescription drugs, which results in lower costs for both patients and healthcare systems. Both sides’ financial burdens may be lessened by this swap.

Improved Accessibility: Making some drugs available over-the-counter (OTC) increases patient access to treatments, especially for common or minor illnesses. This may result in quicker and more convenient medical care, which could cut down on the number of doctor visits.

Customer Demand for Self-Care: The desire among consumers to take charge of their own health and well-being is on the rise. OTC drug availability encourages people to take control of their health, which fuels market expansion.

Pharmaceutical Company Incentives: Changing from prescription to over-the-counter (OTC) treatments can help pharmaceutical companies save money on marketing and distribution expenses, prolong the life of their products, and access new markets.

Regulatory Support and Guidelines: The transition from prescription to over-the-counter medications is facilitated by regulatory agencies such as the FDA in the US. By streamlining the approval procedure, these rules may incentivize more businesses to seek over-the-counter (OTC) status for their goods.

Patent Expirations: In order to maintain market share and prolong the product’s commercial viability, firms may convert branded prescription pharmaceuticals to over-the-counter (OTC) versions once their patents expire.

Innovation and Development of Safer Drugs: The market for Rx to OTC transitions is driven by improvements in drug formulations and safety profiles that enable more medications to meet the requirements for OTC availability.

Efficiency of the Healthcare System: Converting some medications to over-the-counter (OTC) forms can free up resources for healthcare, enabling medical professionals to concentrate on treating more critical ailments and enhancing the system’s overall effectiveness.

Ageing Population: The need for easily available medicines is driven by an ageing population with a rising prevalence of chronic illnesses. Older adults facing persistent health difficulties have a simpler and frequently preferable alternative with over-the-counter (OTC) medications.

Digital Health and Information Accessibility: Consumers are more equipped to make educated decisions about over-the-counter pharmaceuticals thanks to the proliferation of digital health resources and easier access to medical information, which is driving market expansion.

The global Lisinopril Dihydrate market is experiencing robust growth, driven by the increasing prevalence of hypertension and cardiovascular diseases globally. The market, estimated at $250 million in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 5% from 2025 to 2033. This growth is fueled by several factors, including the rising geriatric population (a high-risk group for hypertension), increased awareness of cardiovascular health, and the expanding adoption of Lisinopril Dihydrate as a first-line treatment for hypertension. The pharmaceutical application segment dominates the market, accounting for the majority of Lisinopril Dihydrate consumption, followed by the chemical industry. The high purity segments (99%) command a premium price due to their stringent quality requirements in pharmaceutical applications. Significant regional variations exist, with North America and Europe currently holding substantial market share due to advanced healthcare infrastructure and high rates of cardiovascular disease prevalence. However, Asia-Pacific is anticipated to witness significant growth over the forecast period, driven by increasing healthcare spending and rising disposable incomes in emerging economies like India and China. While the market presents significant opportunities, certain restraints exist. These include potential generic competition, stringent regulatory hurdles for new drug approvals, and fluctuations in raw material prices. However, ongoing research and development in cardiovascular treatments and the continued focus on improving patient outcomes are expected to mitigate these challenges and support the sustained growth of the Lisinopril Dihydrate market. The leading companies in this market are actively investing in R&D, capacity expansion, and strategic partnerships to enhance their market positioning and capitalize on emerging market opportunities. The market segmentation by purity (98% and 99%) reflects the increasing demand for higher purity grades for pharmaceutical applications, further driving market growth and specialization. This comprehensive report provides an in-depth analysis of the global Lisinopril Dihydrate market, projecting robust growth and significant opportunities for stakeholders. We delve into market dynamics, competitive landscapes, and future trends, using rigorous data analysis to provide actionable insights for informed decision-making. Keywords: Lisinopril Dihydrate, ACE inhibitor, pharmaceutical ingredient, market analysis, market trends, industry growth, API, drug manufacturing, chemical synthesis.